OncoMatch/Clinical Trials/NCT05669430
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Is NCT05669430 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including GV20-0251 and GV20-0251 for solid tumor, adult.
Treatment: GV20-0251 · GV20-0251 · GV20-0251 and Pembrolizumab [KEYTRUDA®] · GV20-0251 and Pembrolizumab [KEYTRUDA®] — This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Endometrial Cancer
Colorectal Cancer
Melanoma
Non-Small Cell Lung Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Refractory or intolerant to standard therapy(ies)
Cannot have received: PD-1 and equivalent immune modulators
Treatment with PD-1 and equivalent immune modulators or major surgery prior to the first dose of study medication
Cannot have received: investigational agent
Participants who are currently receiving any other investigational agent or have received an investigational agent within 4 weeks prior to the first dose of study medication
Cannot have received: anticancer treatments
Treatment with any anticancer treatments with 2-weeks prior to the first dose of study medication
Cannot have received: radiation therapy
Exception: Radiation for symptomatic lesions must have been completed prior to the first dose of study medication
Radiation for symptomatic lesions must have been completed prior to the first dose of study medication
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The Angeles Clinic and Research Institute · Los Angeles, California
- HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE · Denver, Colorado
- Yale University · New Haven, Connecticut
- Florida Cancer Specialists & Research Institute, LLC · Fort Myers, Florida
- Community Health Network, Inc. · Indianapolis, Indiana
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify